Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
Filter
Type of Material
Type of Publication
Consortium
Language
  • 1
    Book
    Book
    Tokyo : Princess Takamatsu Cancer Research Fund
    UID:
    (DE-605)HT010079633
    Format: VII, 120 S. : Ill.
    Series Statement: Extended abstracts for the ... international symposium of the Princess Takamatsu Cancer Research Fund 28
    Language: English
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 2
    Book
    Book
    Totowa, NJ : Humana Press
    UID:
    (DE-605)HT016117390
    Format: 270 S. , 23cm
    ISBN: 1603272682 , 9781603272681
    Series Statement: Current cancer research
    Language: English
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 3
    Book
    Book
    Cambridge, Mass. : Elsevier, Academic Press
    UID:
    (DE-627)898805392
    Format: xi, 220 Seiten , Illustrationen (farbig), Diagramme (teilweise farbig) , 23 cm
    Edition: First edition
    ISBN: 9780128119228
    Series Statement: Advances in cancer research volume 135
    Note: Literaturangaben , Chapter One. MicroRNAs and cancer: a long story for short RNAs -- Chapter Two. The enigma of miRNA regulation in cancer -- Chapter Three. Animal models to study microRNA function -- Chapter Four. Cancer hallmarks and microRNAs: the therapeutic connection -- Chapter Five. microRNAs in cancer susceptibility -- Chapter Six. Role of the tRNA-derived small RNAs in cancer: new potential biomarkers and target to therapy -- Chapter Seven. MicroRNAs and epigenetics
    Language: English
    Subjects: Medicine
    RVK:
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 4
    UID:
    (DE-101)1325213454
    Format: Online-Ressource
    ISSN: 1521-4141
    Content: Abstract: Somatic cell hybrids between nonproducer mouse myeloma cells and Burkitt lymphoma‐derived Daudi cells that do not secrete human immunoglobulin chains secrete human IgM. The 33 000 dalton protein (P33) is also secreted by the hybrids as part of the IgM molecule. Since P33 and x chains cosegregate in all primary hybrid clones and subclones, it is concluded that they are coded for by the same human chromosome 2. The fact that both P33 and x' chains are immunoprecipitated by specific anti‐human x chain antisera, and that both P33 and x' bands disappear and a single band immuno‐precipitable by an anti‐human x chain antiserum appears in tunicamycin‐treated hybrid cells, suggest that they are differently glycosylated forms of the same polypeptide.
    In: volume:12
    In: number:8
    In: year:2005
    In: pages:697-701
    In: extent:5
    In: European journal of immunology, Weinheim : Wiley-VCH, 1971-, 12, Heft 8 (2005), 697-701 (gesamt 5), 1521-4141
    Language: English
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 5
    Book
    Book
    Cambridge, MA : Elsevier AP
    UID:
    (DE-605)HT019470792
    Format: xi, 220 Seiten , Illustrationen
    Edition: First edition
    ISBN: 9780128119228
    Series Statement: Advances in cancer research volume 135
    Language: English
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 6
    UID:
    (DE-602)almahu_9949553355602882
    Format: 1 online resource (434 pages) : , illustrations
    ISBN: 0-12-823274-9
    Note: Intro -- MicroRNA in Human Malignancies -- Copyright -- Contents -- Contributors -- Section A: miRNAs involvement in basic mechanisms of cancer development -- Chapter 1 Overview on miRNA classification, biogenesis, and functions -- Introduction -- MicroRNA and the complex biological system of gene expression -- MicroRNA biogenesis, nomenclature, and classification -- Origins of the canonical primary miRNA transcript -- From canonical primary miRNA to mature miRNA -- Noncanonical miRNA biogenesis and isomiRs -- Nomenclature and classification -- Mechanisms of miRNA-mediated gene regulation -- Posttranscriptional regulation of mRNA stability and translation -- Models of miRNA-mediated gene regulation within the nucleus -- The dynamics of miRNA-mediated gene regulation -- MicroRNA abundance and turnover -- Concluding remarks -- References -- Chapter 2 microRNA in cancer: An overview -- The dawn of miRNAs in human biology -- First reported miRNA cancer-associated alterations -- The age of discovery: Microarrays and miRNA cancer signatures -- Functional classification of miRNA: The line between tumor suppressor and oncomiRs -- Development of miRNA as biomarkers -- The transition of miRNA into clinics -- Conclusion and future perspectives -- References -- Chapter 3 miR-15/16 in human malignancies -- 13q deletions in CLL and miR-15/16 -- Other mechanisms of miR-15/16 dysregulation -- Interplay between ROR1, Bcl2, and miR-15/16 in CLL -- miR-15/16 in mice -- miR-15/16 in human AML and MDS -- miR-15/16 in solid cancers -- References -- Chapter 4 microRNAs and tumor suppressor p53 regulation -- p53 and its signaling pathway -- GOF mutant p53 in cancer -- miRNAs regulated by wild-type p53 -- miRNAs that directly regulate p53 -- miRNAs that indirectly regulate p53 -- miRNAs regulated by GOF mutp53 -- Conclusion -- References. , Chapter 5 MicroRNA involvement in invasion and metastasis -- Introduction-The process of metastasis -- Direct regulation of metastasis -- Metastasis-promoting miRNAs -- Metastasis-Suppressing miRNAs -- Indirect regulation of metastasis -- Regulation of miRNA biosynthesis -- RNA-RNA interaction-based miRNA regulation -- Translational application of metastasis-associated miRNAs -- Noninvasive biomarkers -- miRNAs as therapeutics -- Conclusions and perspectives -- Acknowledgment -- References -- Chapter 6 microRNAs and metabolism -- Introduction -- Trafficking and consumption of glucose -- NcRNAs regulate glucose trafficking in cancer cells by altering GLUT levels -- NcRNAs regulate key glycolytic enzymes -- Branched pathways of glycolysis -- NcRNAs can influence glucose metabolism by regulating cancer-associated signaling pathways -- PI3K/Akt/mTOR and HIF-1 signaling pathway -- p53 signaling pathway -- Conclusion and future perspectives -- References -- Chapter 7 microRNAs in inflammation processes -- Introduction -- MiRNA biogenesis and functions -- Inflammation and mechanism of activation -- miRNAs in inflammatory disease -- Chronic respiratory diseases -- Cystic fibrosis (CF) -- Chronic obstructive pulmonary disease (COPD) -- Asthma -- Cardiovascular diseases -- Atherosclerosis -- Myocardial infarction (MI) and ischemia reperfusion injury (MIRI) -- Autoimmune diseases -- Systemic lupus erythematosus (SLE) -- Rheumatoid arthritis (RA) -- Multiple sclerosis (MS) -- Cancer -- Colorectal cancer (CRC) -- Lung cancer (LC) -- Prostate cancer (PC) -- Conclusion -- References -- Section B: miRNAs methodologies -- Chapter 8 Wet-lab methods for miRNA analysis -- Introduction -- Methods for miRNA discovery and detection -- Northern blot -- Hybridization microarrays -- Quantitative PCR -- Next-generation sequencing -- Functional miRNA analysis. , Classical target validation methods: Reporter genes and RISC immunoprecipitation -- High-throughput methods for target identification -- Functional validation -- Final remarks -- Acknowledgments -- References -- Chapter 9 Bioinformatics utilities, web resources and integrative strategies for the analysis of miRNA regulatory networks -- Introduction -- Target prediction algorithms -- Single predictors -- Multiple predictors -- In silico functional assessment of miRNAs: Tips and tricks -- Functional analysis of miRNAs associated with survival time in lung adenocarcinoma: A test case -- Conclusions -- Acknowledgments -- References -- Chapter 10 Computational resources for analysis of miRNA targetome -- Introduction -- miRNA target databases -- miRNA target databases for human -- miRNA target databases for other species -- miRNA algorithms -- miRNA target prediction for humans -- miRNA target prediction for other species -- miRNA target prediction for plants -- Conclusion -- References -- Chapter 11 miRNA bioinformatics and pathway analysis -- The microRNA synergy -- Role of microRNAs in biological signaling pathways -- Pathways: The manually curated maps of the cell interactome -- The miRNA interactome -- miRNA pathway analysis methods -- ORA on miRNA targets -- FCS on miRNA targets -- Topological approaches of pathway analysis with miRNAs -- Computational tools for miRNA pathway analyses -- Conclusions -- Funding -- References -- Section C: miRNAs involvement in therapeutics/theranostics -- Chapter 12 Opportunities of miRNAs in cancer therapeutics -- Introduction -- MicroRNAs in cancer. OncomiRs and tumor-suppressor miRNAs -- Alterations in miRNAs and their appeal for cancer therapy -- MicroRNA-based drug design -- Choosing the therapeutic strategy: miRNA mimics, antagomiRs, and more -- Chemical modifications of RNA-based drugs. , Delivery of RNA-based drugs -- Chemical modifications -- Liposomes, micelles, and exosomes -- Nanoparticles -- Viral vectors -- Bacteria-based vectors (EDV nanocells) -- MicroRNA-based therapeutics in the current clinic -- MRX34 -- Cobomarsen -- TargomiRs -- Remlarsen -- Other preclinical studies -- The future of miRNAs in the clinic -- Current challenges in the use of miRNAs -- Quick degradation in the bloodstream -- Extrahepatic delivery to tumor site -- Limited tissue penetration -- Endocytosis and endosome entrapment -- Off-targets and side effects -- Other challenges -- Future perspectives -- References -- Section D: miRNAs involvement in human cancer: Pathophysiology and translational opportunities -- Chapter 13 Pathophysiology roles and translational opportunities of miRNAs in acute leukemias -- Introduction -- MiRNAs involved in the pathogenesis of AML -- miRNAs as biomarkers -- miRNAs in chemoresistance -- miRNAs as therapeutic targets -- Role of miR-15/16 clusters in AML pathogenesis -- Conclusions -- References -- Chapter 14 Pathophysiology roles and translational opportunities of miRNAs in CLL -- MicroRNAs and the cellular origin of CLL cells -- MicroRNAs and CLL genetics -- microRNAs in proliferation and survival of CLL cells -- microRNAs and BCR signaling -- MicroRNAs and microenvironment -- MicroRNAs and apoptosis -- Translational opportunities -- References -- Chapter 15 Pathophysiology roles and translational opportunities of miRNAs in lymphoma -- Summary -- miRNAs and pathophysiology -- miRNAs regulate the expression of genes that promote B-cell differentiation -- Lymphomagenesis -- DLBCL and miRNA -- MZL and miRNA -- Diagnosis -- Prognosis -- References -- Chapter 16 Pathophysiology roles and translational opportunities of miRNAs in breast cancer -- Breast physiology and pathology -- Breast physiology -- Breast pathology. , MicroRNAs in breast physiology -- MicroRNAs in breast cancer -- Oncosuppressive and oncogenic miRNAs -- From biology to the clinics: microRNAs as biomarkers (tissue and ct-miRNAs) of diagnosis, prognosis, and resistance to ther ... -- From biology to the clinics: Is a miRNA-therapy feasible? -- Conclusions -- References -- Chapter 17 Pathophysiology roles and translational opportunities of miRNAs in colorectal cancer -- Introduction -- Involvement of miRNAs in the pathophysiology of CRC -- Wnt/ β -catenin signaling pathway -- EGFR signaling -- TGF- β signaling pathway -- Notch signaling pathway -- Cell cycle regulation -- Regulation of apoptosis -- Regulation of angiogenesis -- Regulation of epithelial-to-mesenchymal transition and metastatic capacity -- Reprogramming of cellular metabolism -- Involvement in tumor immunosurveillance -- The interconnection between miRNAs and epigenetics in CRC -- Translational opportunities of miRNAs in CRC -- Expression profiling of miRNAs in CRC patients -- Circulating and fecal miRNAs as promising biomarkers for early CRC detection -- Prognostic and predictive potential of miRNAs in CRC -- Perspectives and future challenges -- Funding -- References -- Chapter 18 Pathophysiology roles and translational opportunities of miRNAs in lung cancer -- Pathophysiology -- MicroRNA expressed in lung tumor cells -- MicroRNA expressed in lung microenvironmental cells -- Tissutal miRNAs as diagnostic or prognostic biomarkers -- Circulating miRNAs -- Circulating miRNAs for lung cancer diagnosis -- Circulating miRNAs as predictive and prognostic biomarkers in lung cancer patients -- Analysis of circulating miRNAs: Issues and solutions -- References -- Chapter 19 Pathophysiology roles and translational opportunities of miRNAs in mesothelioma -- Introduction -- miRNAs as biomarkers for MPM diagnosis. , miRNAs as biomarkers for malignant pleural mesothelioma prognosis.
    Additional Edition: ISBN 0-12-822287-5
    Language: English
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 7
    UID:
    (DE-602)edoccha_9960161480302883
    Format: 1 online resource (434 pages) : , illustrations
    ISBN: 0-12-823274-9
    Note: Intro -- MicroRNA in Human Malignancies -- Copyright -- Contents -- Contributors -- Section A: miRNAs involvement in basic mechanisms of cancer development -- Chapter 1 Overview on miRNA classification, biogenesis, and functions -- Introduction -- MicroRNA and the complex biological system of gene expression -- MicroRNA biogenesis, nomenclature, and classification -- Origins of the canonical primary miRNA transcript -- From canonical primary miRNA to mature miRNA -- Noncanonical miRNA biogenesis and isomiRs -- Nomenclature and classification -- Mechanisms of miRNA-mediated gene regulation -- Posttranscriptional regulation of mRNA stability and translation -- Models of miRNA-mediated gene regulation within the nucleus -- The dynamics of miRNA-mediated gene regulation -- MicroRNA abundance and turnover -- Concluding remarks -- References -- Chapter 2 microRNA in cancer: An overview -- The dawn of miRNAs in human biology -- First reported miRNA cancer-associated alterations -- The age of discovery: Microarrays and miRNA cancer signatures -- Functional classification of miRNA: The line between tumor suppressor and oncomiRs -- Development of miRNA as biomarkers -- The transition of miRNA into clinics -- Conclusion and future perspectives -- References -- Chapter 3 miR-15/16 in human malignancies -- 13q deletions in CLL and miR-15/16 -- Other mechanisms of miR-15/16 dysregulation -- Interplay between ROR1, Bcl2, and miR-15/16 in CLL -- miR-15/16 in mice -- miR-15/16 in human AML and MDS -- miR-15/16 in solid cancers -- References -- Chapter 4 microRNAs and tumor suppressor p53 regulation -- p53 and its signaling pathway -- GOF mutant p53 in cancer -- miRNAs regulated by wild-type p53 -- miRNAs that directly regulate p53 -- miRNAs that indirectly regulate p53 -- miRNAs regulated by GOF mutp53 -- Conclusion -- References. , Chapter 5 MicroRNA involvement in invasion and metastasis -- Introduction-The process of metastasis -- Direct regulation of metastasis -- Metastasis-promoting miRNAs -- Metastasis-Suppressing miRNAs -- Indirect regulation of metastasis -- Regulation of miRNA biosynthesis -- RNA-RNA interaction-based miRNA regulation -- Translational application of metastasis-associated miRNAs -- Noninvasive biomarkers -- miRNAs as therapeutics -- Conclusions and perspectives -- Acknowledgment -- References -- Chapter 6 microRNAs and metabolism -- Introduction -- Trafficking and consumption of glucose -- NcRNAs regulate glucose trafficking in cancer cells by altering GLUT levels -- NcRNAs regulate key glycolytic enzymes -- Branched pathways of glycolysis -- NcRNAs can influence glucose metabolism by regulating cancer-associated signaling pathways -- PI3K/Akt/mTOR and HIF-1 signaling pathway -- p53 signaling pathway -- Conclusion and future perspectives -- References -- Chapter 7 microRNAs in inflammation processes -- Introduction -- MiRNA biogenesis and functions -- Inflammation and mechanism of activation -- miRNAs in inflammatory disease -- Chronic respiratory diseases -- Cystic fibrosis (CF) -- Chronic obstructive pulmonary disease (COPD) -- Asthma -- Cardiovascular diseases -- Atherosclerosis -- Myocardial infarction (MI) and ischemia reperfusion injury (MIRI) -- Autoimmune diseases -- Systemic lupus erythematosus (SLE) -- Rheumatoid arthritis (RA) -- Multiple sclerosis (MS) -- Cancer -- Colorectal cancer (CRC) -- Lung cancer (LC) -- Prostate cancer (PC) -- Conclusion -- References -- Section B: miRNAs methodologies -- Chapter 8 Wet-lab methods for miRNA analysis -- Introduction -- Methods for miRNA discovery and detection -- Northern blot -- Hybridization microarrays -- Quantitative PCR -- Next-generation sequencing -- Functional miRNA analysis. , Classical target validation methods: Reporter genes and RISC immunoprecipitation -- High-throughput methods for target identification -- Functional validation -- Final remarks -- Acknowledgments -- References -- Chapter 9 Bioinformatics utilities, web resources and integrative strategies for the analysis of miRNA regulatory networks -- Introduction -- Target prediction algorithms -- Single predictors -- Multiple predictors -- In silico functional assessment of miRNAs: Tips and tricks -- Functional analysis of miRNAs associated with survival time in lung adenocarcinoma: A test case -- Conclusions -- Acknowledgments -- References -- Chapter 10 Computational resources for analysis of miRNA targetome -- Introduction -- miRNA target databases -- miRNA target databases for human -- miRNA target databases for other species -- miRNA algorithms -- miRNA target prediction for humans -- miRNA target prediction for other species -- miRNA target prediction for plants -- Conclusion -- References -- Chapter 11 miRNA bioinformatics and pathway analysis -- The microRNA synergy -- Role of microRNAs in biological signaling pathways -- Pathways: The manually curated maps of the cell interactome -- The miRNA interactome -- miRNA pathway analysis methods -- ORA on miRNA targets -- FCS on miRNA targets -- Topological approaches of pathway analysis with miRNAs -- Computational tools for miRNA pathway analyses -- Conclusions -- Funding -- References -- Section C: miRNAs involvement in therapeutics/theranostics -- Chapter 12 Opportunities of miRNAs in cancer therapeutics -- Introduction -- MicroRNAs in cancer. OncomiRs and tumor-suppressor miRNAs -- Alterations in miRNAs and their appeal for cancer therapy -- MicroRNA-based drug design -- Choosing the therapeutic strategy: miRNA mimics, antagomiRs, and more -- Chemical modifications of RNA-based drugs. , Delivery of RNA-based drugs -- Chemical modifications -- Liposomes, micelles, and exosomes -- Nanoparticles -- Viral vectors -- Bacteria-based vectors (EDV nanocells) -- MicroRNA-based therapeutics in the current clinic -- MRX34 -- Cobomarsen -- TargomiRs -- Remlarsen -- Other preclinical studies -- The future of miRNAs in the clinic -- Current challenges in the use of miRNAs -- Quick degradation in the bloodstream -- Extrahepatic delivery to tumor site -- Limited tissue penetration -- Endocytosis and endosome entrapment -- Off-targets and side effects -- Other challenges -- Future perspectives -- References -- Section D: miRNAs involvement in human cancer: Pathophysiology and translational opportunities -- Chapter 13 Pathophysiology roles and translational opportunities of miRNAs in acute leukemias -- Introduction -- MiRNAs involved in the pathogenesis of AML -- miRNAs as biomarkers -- miRNAs in chemoresistance -- miRNAs as therapeutic targets -- Role of miR-15/16 clusters in AML pathogenesis -- Conclusions -- References -- Chapter 14 Pathophysiology roles and translational opportunities of miRNAs in CLL -- MicroRNAs and the cellular origin of CLL cells -- MicroRNAs and CLL genetics -- microRNAs in proliferation and survival of CLL cells -- microRNAs and BCR signaling -- MicroRNAs and microenvironment -- MicroRNAs and apoptosis -- Translational opportunities -- References -- Chapter 15 Pathophysiology roles and translational opportunities of miRNAs in lymphoma -- Summary -- miRNAs and pathophysiology -- miRNAs regulate the expression of genes that promote B-cell differentiation -- Lymphomagenesis -- DLBCL and miRNA -- MZL and miRNA -- Diagnosis -- Prognosis -- References -- Chapter 16 Pathophysiology roles and translational opportunities of miRNAs in breast cancer -- Breast physiology and pathology -- Breast physiology -- Breast pathology. , MicroRNAs in breast physiology -- MicroRNAs in breast cancer -- Oncosuppressive and oncogenic miRNAs -- From biology to the clinics: microRNAs as biomarkers (tissue and ct-miRNAs) of diagnosis, prognosis, and resistance to ther ... -- From biology to the clinics: Is a miRNA-therapy feasible? -- Conclusions -- References -- Chapter 17 Pathophysiology roles and translational opportunities of miRNAs in colorectal cancer -- Introduction -- Involvement of miRNAs in the pathophysiology of CRC -- Wnt/ β -catenin signaling pathway -- EGFR signaling -- TGF- β signaling pathway -- Notch signaling pathway -- Cell cycle regulation -- Regulation of apoptosis -- Regulation of angiogenesis -- Regulation of epithelial-to-mesenchymal transition and metastatic capacity -- Reprogramming of cellular metabolism -- Involvement in tumor immunosurveillance -- The interconnection between miRNAs and epigenetics in CRC -- Translational opportunities of miRNAs in CRC -- Expression profiling of miRNAs in CRC patients -- Circulating and fecal miRNAs as promising biomarkers for early CRC detection -- Prognostic and predictive potential of miRNAs in CRC -- Perspectives and future challenges -- Funding -- References -- Chapter 18 Pathophysiology roles and translational opportunities of miRNAs in lung cancer -- Pathophysiology -- MicroRNA expressed in lung tumor cells -- MicroRNA expressed in lung microenvironmental cells -- Tissutal miRNAs as diagnostic or prognostic biomarkers -- Circulating miRNAs -- Circulating miRNAs for lung cancer diagnosis -- Circulating miRNAs as predictive and prognostic biomarkers in lung cancer patients -- Analysis of circulating miRNAs: Issues and solutions -- References -- Chapter 19 Pathophysiology roles and translational opportunities of miRNAs in mesothelioma -- Introduction -- miRNAs as biomarkers for MPM diagnosis. , miRNAs as biomarkers for malignant pleural mesothelioma prognosis.
    Additional Edition: ISBN 0-12-822287-5
    Language: English
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 8
    Online Resource
    Online Resource
    San Diego : Elsevier Science & Technology
    UID:
    (DE-627)1793934762
    Format: 1 online resource (434 pages)
    ISBN: 9780128232743
    Note: Description based on publisher supplied metadata and other sources
    Language: English
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 9
    Online Resource
    Online Resource
    London : Elsevier
    UID:
    (DE-627)1833030222
    Format: 1 Online-Ressource
    ISBN: 9780128232743 , 0128232749
    Note: Intro -- MicroRNA in Human Malignancies -- Copyright -- Contents -- Contributors -- Section A: miRNAs involvement in basic mechanisms of cancer development -- Chapter 1 Overview on miRNA classification, biogenesis, and functions -- Introduction -- MicroRNA and the complex biological system of gene expression -- MicroRNA biogenesis, nomenclature, and classification -- Origins of the canonical primary miRNA transcript -- From canonical primary miRNA to mature miRNA -- Noncanonical miRNA biogenesis and isomiRs -- Nomenclature and classification -- Mechanisms of miRNA-mediated gene regulation -- Posttranscriptional regulation of mRNA stability and translation -- Models of miRNA-mediated gene regulation within the nucleus -- The dynamics of miRNA-mediated gene regulation -- MicroRNA abundance and turnover -- Concluding remarks -- References -- Chapter 2 microRNA in cancer: An overview -- The dawn of miRNAs in human biology -- First reported miRNA cancer-associated alterations -- The age of discovery: Microarrays and miRNA cancer signatures -- Functional classification of miRNA: The line between tumor suppressor and oncomiRs -- Development of miRNA as biomarkers -- The transition of miRNA into clinics -- Conclusion and future perspectives -- References -- Chapter 3 miR-15/16 in human malignancies -- 13q deletions in CLL and miR-15/16 -- Other mechanisms of miR-15/16 dysregulation -- Interplay between ROR1, Bcl2, and miR-15/16 in CLL -- miR-15/16 in mice -- miR-15/16 in human AML and MDS -- miR-15/16 in solid cancers -- References -- Chapter 4 microRNAs and tumor suppressor p53 regulation -- p53 and its signaling pathway -- GOF mutant p53 in cancer -- miRNAs regulated by wild-type p53 -- miRNAs that directly regulate p53 -- miRNAs that indirectly regulate p53 -- miRNAs regulated by GOF mutp53 -- Conclusion -- References. , Chapter 5 MicroRNA involvement in invasion and metastasis -- Introduction-The process of metastasis -- Direct regulation of metastasis -- Metastasis-promoting miRNAs -- Metastasis-Suppressing miRNAs -- Indirect regulation of metastasis -- Regulation of miRNA biosynthesis -- RNA-RNA interaction-based miRNA regulation -- Translational application of metastasis-associated miRNAs -- Noninvasive biomarkers -- miRNAs as therapeutics -- Conclusions and perspectives -- Acknowledgment -- References -- Chapter 6 microRNAs and metabolism -- Introduction -- Trafficking and consumption of glucose -- NcRNAs regulate glucose trafficking in cancer cells by altering GLUT levels -- NcRNAs regulate key glycolytic enzymes -- Branched pathways of glycolysis -- NcRNAs can influence glucose metabolism by regulating cancer-associated signaling pathways -- PI3K/Akt/mTOR and HIF-1 signaling pathway -- p53 signaling pathway -- Conclusion and future perspectives -- References -- Chapter 7 microRNAs in inflammation processes -- Introduction -- MiRNA biogenesis and functions -- Inflammation and mechanism of activation -- miRNAs in inflammatory disease -- Chronic respiratory diseases -- Cystic fibrosis (CF) -- Chronic obstructive pulmonary disease (COPD) -- Asthma -- Cardiovascular diseases -- Atherosclerosis -- Myocardial infarction (MI) and ischemia reperfusion injury (MIRI) -- Autoimmune diseases -- Systemic lupus erythematosus (SLE) -- Rheumatoid arthritis (RA) -- Multiple sclerosis (MS) -- Cancer -- Colorectal cancer (CRC) -- Lung cancer (LC) -- Prostate cancer (PC) -- Conclusion -- References -- Section B: miRNAs methodologies -- Chapter 8 Wet-lab methods for miRNA analysis -- Introduction -- Methods for miRNA discovery and detection -- Northern blot -- Hybridization microarrays -- Quantitative PCR -- Next-generation sequencing -- Functional miRNA analysis. , Classical target validation methods: Reporter genes and RISC immunoprecipitation -- High-throughput methods for target identification -- Functional validation -- Final remarks -- Acknowledgments -- References -- Chapter 9 Bioinformatics utilities, web resources and integrative strategies for the analysis of miRNA regulatory networks -- Introduction -- Target prediction algorithms -- Single predictors -- Multiple predictors -- In silico functional assessment of miRNAs: Tips and tricks -- Functional analysis of miRNAs associated with survival time in lung adenocarcinoma: A test case -- Conclusions -- Acknowledgments -- References -- Chapter 10 Computational resources for analysis of miRNA targetome -- Introduction -- miRNA target databases -- miRNA target databases for human -- miRNA target databases for other species -- miRNA algorithms -- miRNA target prediction for humans -- miRNA target prediction for other species -- miRNA target prediction for plants -- Conclusion -- References -- Chapter 11 miRNA bioinformatics and pathway analysis -- The microRNA synergy -- Role of microRNAs in biological signaling pathways -- Pathways: The manually curated maps of the cell interactome -- The miRNA interactome -- miRNA pathway analysis methods -- ORA on miRNA targets -- FCS on miRNA targets -- Topological approaches of pathway analysis with miRNAs -- Computational tools for miRNA pathway analyses -- Conclusions -- Funding -- References -- Section C: miRNAs involvement in therapeutics/theranostics -- Chapter 12 Opportunities of miRNAs in cancer therapeutics -- Introduction -- MicroRNAs in cancer. OncomiRs and tumor-suppressor miRNAs -- Alterations in miRNAs and their appeal for cancer therapy -- MicroRNA-based drug design -- Choosing the therapeutic strategy: miRNA mimics, antagomiRs, and more -- Chemical modifications of RNA-based drugs. , Delivery of RNA-based drugs -- Chemical modifications -- Liposomes, micelles, and exosomes -- Nanoparticles -- Viral vectors -- Bacteria-based vectors (EDV nanocells) -- MicroRNA-based therapeutics in the current clinic -- MRX34 -- Cobomarsen -- TargomiRs -- Remlarsen -- Other preclinical studies -- The future of miRNAs in the clinic -- Current challenges in the use of miRNAs -- Quick degradation in the bloodstream -- Extrahepatic delivery to tumor site -- Limited tissue penetration -- Endocytosis and endosome entrapment -- Off-targets and side effects -- Other challenges -- Future perspectives -- References -- Section D: miRNAs involvement in human cancer: Pathophysiology and translational opportunities -- Chapter 13 Pathophysiology roles and translational opportunities of miRNAs in acute leukemias -- Introduction -- MiRNAs involved in the pathogenesis of AML -- miRNAs as biomarkers -- miRNAs in chemoresistance -- miRNAs as therapeutic targets -- Role of miR-15/16 clusters in AML pathogenesis -- Conclusions -- References -- Chapter 14 Pathophysiology roles and translational opportunities of miRNAs in CLL -- MicroRNAs and the cellular origin of CLL cells -- MicroRNAs and CLL genetics -- microRNAs in proliferation and survival of CLL cells -- microRNAs and BCR signaling -- MicroRNAs and microenvironment -- MicroRNAs and apoptosis -- Translational opportunities -- References -- Chapter 15 Pathophysiology roles and translational opportunities of miRNAs in lymphoma -- Summary -- miRNAs and pathophysiology -- miRNAs regulate the expression of genes that promote B-cell differentiation -- Lymphomagenesis -- DLBCL and miRNA -- MZL and miRNA -- Diagnosis -- Prognosis -- References -- Chapter 16 Pathophysiology roles and translational opportunities of miRNAs in breast cancer -- Breast physiology and pathology -- Breast physiology -- Breast pathology.
    Additional Edition: Erscheint auch als 0128222875
    Additional Edition: 9780128222874
    Language: English
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
  • 10
    UID:
    (DE-602)edocfu_9960161480302883
    Format: 1 online resource (434 pages) : , illustrations
    ISBN: 0-12-823274-9
    Note: Intro -- MicroRNA in Human Malignancies -- Copyright -- Contents -- Contributors -- Section A: miRNAs involvement in basic mechanisms of cancer development -- Chapter 1 Overview on miRNA classification, biogenesis, and functions -- Introduction -- MicroRNA and the complex biological system of gene expression -- MicroRNA biogenesis, nomenclature, and classification -- Origins of the canonical primary miRNA transcript -- From canonical primary miRNA to mature miRNA -- Noncanonical miRNA biogenesis and isomiRs -- Nomenclature and classification -- Mechanisms of miRNA-mediated gene regulation -- Posttranscriptional regulation of mRNA stability and translation -- Models of miRNA-mediated gene regulation within the nucleus -- The dynamics of miRNA-mediated gene regulation -- MicroRNA abundance and turnover -- Concluding remarks -- References -- Chapter 2 microRNA in cancer: An overview -- The dawn of miRNAs in human biology -- First reported miRNA cancer-associated alterations -- The age of discovery: Microarrays and miRNA cancer signatures -- Functional classification of miRNA: The line between tumor suppressor and oncomiRs -- Development of miRNA as biomarkers -- The transition of miRNA into clinics -- Conclusion and future perspectives -- References -- Chapter 3 miR-15/16 in human malignancies -- 13q deletions in CLL and miR-15/16 -- Other mechanisms of miR-15/16 dysregulation -- Interplay between ROR1, Bcl2, and miR-15/16 in CLL -- miR-15/16 in mice -- miR-15/16 in human AML and MDS -- miR-15/16 in solid cancers -- References -- Chapter 4 microRNAs and tumor suppressor p53 regulation -- p53 and its signaling pathway -- GOF mutant p53 in cancer -- miRNAs regulated by wild-type p53 -- miRNAs that directly regulate p53 -- miRNAs that indirectly regulate p53 -- miRNAs regulated by GOF mutp53 -- Conclusion -- References. , Chapter 5 MicroRNA involvement in invasion and metastasis -- Introduction-The process of metastasis -- Direct regulation of metastasis -- Metastasis-promoting miRNAs -- Metastasis-Suppressing miRNAs -- Indirect regulation of metastasis -- Regulation of miRNA biosynthesis -- RNA-RNA interaction-based miRNA regulation -- Translational application of metastasis-associated miRNAs -- Noninvasive biomarkers -- miRNAs as therapeutics -- Conclusions and perspectives -- Acknowledgment -- References -- Chapter 6 microRNAs and metabolism -- Introduction -- Trafficking and consumption of glucose -- NcRNAs regulate glucose trafficking in cancer cells by altering GLUT levels -- NcRNAs regulate key glycolytic enzymes -- Branched pathways of glycolysis -- NcRNAs can influence glucose metabolism by regulating cancer-associated signaling pathways -- PI3K/Akt/mTOR and HIF-1 signaling pathway -- p53 signaling pathway -- Conclusion and future perspectives -- References -- Chapter 7 microRNAs in inflammation processes -- Introduction -- MiRNA biogenesis and functions -- Inflammation and mechanism of activation -- miRNAs in inflammatory disease -- Chronic respiratory diseases -- Cystic fibrosis (CF) -- Chronic obstructive pulmonary disease (COPD) -- Asthma -- Cardiovascular diseases -- Atherosclerosis -- Myocardial infarction (MI) and ischemia reperfusion injury (MIRI) -- Autoimmune diseases -- Systemic lupus erythematosus (SLE) -- Rheumatoid arthritis (RA) -- Multiple sclerosis (MS) -- Cancer -- Colorectal cancer (CRC) -- Lung cancer (LC) -- Prostate cancer (PC) -- Conclusion -- References -- Section B: miRNAs methodologies -- Chapter 8 Wet-lab methods for miRNA analysis -- Introduction -- Methods for miRNA discovery and detection -- Northern blot -- Hybridization microarrays -- Quantitative PCR -- Next-generation sequencing -- Functional miRNA analysis. , Classical target validation methods: Reporter genes and RISC immunoprecipitation -- High-throughput methods for target identification -- Functional validation -- Final remarks -- Acknowledgments -- References -- Chapter 9 Bioinformatics utilities, web resources and integrative strategies for the analysis of miRNA regulatory networks -- Introduction -- Target prediction algorithms -- Single predictors -- Multiple predictors -- In silico functional assessment of miRNAs: Tips and tricks -- Functional analysis of miRNAs associated with survival time in lung adenocarcinoma: A test case -- Conclusions -- Acknowledgments -- References -- Chapter 10 Computational resources for analysis of miRNA targetome -- Introduction -- miRNA target databases -- miRNA target databases for human -- miRNA target databases for other species -- miRNA algorithms -- miRNA target prediction for humans -- miRNA target prediction for other species -- miRNA target prediction for plants -- Conclusion -- References -- Chapter 11 miRNA bioinformatics and pathway analysis -- The microRNA synergy -- Role of microRNAs in biological signaling pathways -- Pathways: The manually curated maps of the cell interactome -- The miRNA interactome -- miRNA pathway analysis methods -- ORA on miRNA targets -- FCS on miRNA targets -- Topological approaches of pathway analysis with miRNAs -- Computational tools for miRNA pathway analyses -- Conclusions -- Funding -- References -- Section C: miRNAs involvement in therapeutics/theranostics -- Chapter 12 Opportunities of miRNAs in cancer therapeutics -- Introduction -- MicroRNAs in cancer. OncomiRs and tumor-suppressor miRNAs -- Alterations in miRNAs and their appeal for cancer therapy -- MicroRNA-based drug design -- Choosing the therapeutic strategy: miRNA mimics, antagomiRs, and more -- Chemical modifications of RNA-based drugs. , Delivery of RNA-based drugs -- Chemical modifications -- Liposomes, micelles, and exosomes -- Nanoparticles -- Viral vectors -- Bacteria-based vectors (EDV nanocells) -- MicroRNA-based therapeutics in the current clinic -- MRX34 -- Cobomarsen -- TargomiRs -- Remlarsen -- Other preclinical studies -- The future of miRNAs in the clinic -- Current challenges in the use of miRNAs -- Quick degradation in the bloodstream -- Extrahepatic delivery to tumor site -- Limited tissue penetration -- Endocytosis and endosome entrapment -- Off-targets and side effects -- Other challenges -- Future perspectives -- References -- Section D: miRNAs involvement in human cancer: Pathophysiology and translational opportunities -- Chapter 13 Pathophysiology roles and translational opportunities of miRNAs in acute leukemias -- Introduction -- MiRNAs involved in the pathogenesis of AML -- miRNAs as biomarkers -- miRNAs in chemoresistance -- miRNAs as therapeutic targets -- Role of miR-15/16 clusters in AML pathogenesis -- Conclusions -- References -- Chapter 14 Pathophysiology roles and translational opportunities of miRNAs in CLL -- MicroRNAs and the cellular origin of CLL cells -- MicroRNAs and CLL genetics -- microRNAs in proliferation and survival of CLL cells -- microRNAs and BCR signaling -- MicroRNAs and microenvironment -- MicroRNAs and apoptosis -- Translational opportunities -- References -- Chapter 15 Pathophysiology roles and translational opportunities of miRNAs in lymphoma -- Summary -- miRNAs and pathophysiology -- miRNAs regulate the expression of genes that promote B-cell differentiation -- Lymphomagenesis -- DLBCL and miRNA -- MZL and miRNA -- Diagnosis -- Prognosis -- References -- Chapter 16 Pathophysiology roles and translational opportunities of miRNAs in breast cancer -- Breast physiology and pathology -- Breast physiology -- Breast pathology. , MicroRNAs in breast physiology -- MicroRNAs in breast cancer -- Oncosuppressive and oncogenic miRNAs -- From biology to the clinics: microRNAs as biomarkers (tissue and ct-miRNAs) of diagnosis, prognosis, and resistance to ther ... -- From biology to the clinics: Is a miRNA-therapy feasible? -- Conclusions -- References -- Chapter 17 Pathophysiology roles and translational opportunities of miRNAs in colorectal cancer -- Introduction -- Involvement of miRNAs in the pathophysiology of CRC -- Wnt/ β -catenin signaling pathway -- EGFR signaling -- TGF- β signaling pathway -- Notch signaling pathway -- Cell cycle regulation -- Regulation of apoptosis -- Regulation of angiogenesis -- Regulation of epithelial-to-mesenchymal transition and metastatic capacity -- Reprogramming of cellular metabolism -- Involvement in tumor immunosurveillance -- The interconnection between miRNAs and epigenetics in CRC -- Translational opportunities of miRNAs in CRC -- Expression profiling of miRNAs in CRC patients -- Circulating and fecal miRNAs as promising biomarkers for early CRC detection -- Prognostic and predictive potential of miRNAs in CRC -- Perspectives and future challenges -- Funding -- References -- Chapter 18 Pathophysiology roles and translational opportunities of miRNAs in lung cancer -- Pathophysiology -- MicroRNA expressed in lung tumor cells -- MicroRNA expressed in lung microenvironmental cells -- Tissutal miRNAs as diagnostic or prognostic biomarkers -- Circulating miRNAs -- Circulating miRNAs for lung cancer diagnosis -- Circulating miRNAs as predictive and prognostic biomarkers in lung cancer patients -- Analysis of circulating miRNAs: Issues and solutions -- References -- Chapter 19 Pathophysiology roles and translational opportunities of miRNAs in mesothelioma -- Introduction -- miRNAs as biomarkers for MPM diagnosis. , miRNAs as biomarkers for malignant pleural mesothelioma prognosis.
    Additional Edition: ISBN 0-12-822287-5
    Language: English
    Library Location Call Number Volume/Issue/Year Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. Further information can be found on the KOBV privacy pages